[ad_1]
The covid-19 vaccine developed by Pfizer and BioNTech now appears to be 95% and 94% overall effective in people over 65. The companies say they will now apply for authorization for emergency use of the vaccine in the United States “in a few days.”
The Pfizer-BioNTech vaccine has now proven to be 95% effective in preventing coronavirus and has met the safety criteria required for emergency dispatch, the companies announced Wednesday, according to international press.
New data from the ongoing phase three trial suggests that the vaccine works equally well in people of all races and ethnicities, the BBC said.
The results are based on two doses given to more than 41,000 people around the world.
Last week, Pfizer and BioNTech released preliminary data showing that the vaccine offers 90% protection against COVID-19 and there were no safety concerns.
The US pharmaceutical company is preparing to apply for emergency approval of its COVID-19 vaccine, company president Albert Bourla said on Tuesday.
Bourla made the statement at a forum hosted by The New York Times and STAT News, after his company and German partner BioNTech announced on November 9 that the vaccine is more than 90% effective.
“We are very close to requesting an emergency authorization,” said the head of the pharmaceutical company, who did not want to give a specific date.
According to Bourla, Pfizer has already collected the safety data required by health authorities, which require manufacturers to monitor at least half of the people who received the vaccine during phase 3 trials for two months.
Following the announcement by Pfizer and BioNTech, the modern biotech company on Monday announced test results for its vaccine project, which point to an efficiency of around 94%.
Bourla, at the STAT News forum, said he was relieved to learn that there is another successful vaccine and expressed confidence that there will be even more, given that global demand will be greater than the capacity of any company.
When they announced the success of their trials, Pfizer and BioNTech indicated that they expect to produce 50 million doses this year and 1.3 billion doses in 2021.
[ad_2]
